Vitiligo

What Should NPs and PAs Know About Skin Cancer Risk in Vitiligo?

about 2 months ago

A meta-analysis found significantly lower SCC risk in patients with vitiligo, offering useful context for skin cancer and phototherapy counseling.

Latest News

Breakout Bulletin: July 13-July 17 3 months ago

Breakout Bulletin: July 6-July 10 3 months ago

Journal Digest: June 24, 2026 4 months ago

Higher Initial Dosing in Excimer Laser Therapy Yields Faster Vitiligo Repigmentation with Fewer Sessions 5 months ago

Continuing Medical Education

In-Person Event

DermNexus: The Inflammatory Disease and Innovations Congress for NP/PAs

November 20-21, 2026

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Video

Publication Review: Defining On-Treatment Remission in Plaque Psoriasis

April W. Armstrong, MD, MPH; Tina Bhutani-Jacques MD

All News

Cross-Cultural Drivers of Psychosocial Burden in Vitiligo

ByMaddi Hebebrand, MC, Associate Editor

March 24th 2026

Misconceptions about vitiligo, including contagion and supernatural causation, remain prevalent in many regions and are linked to increased stigma.

TRuE-V Data Suggest 2 Years Is the True Benchmark for Ruxolitinib Response

ByMaddi Hebebrand, MC, Associate Editor

March 23rd 2026

In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use.

Vitiligo

Latest News

Continuing Medical Education

DermNexus: The Inflammatory Disease and Innovations Congress for NP/PAs

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Publication Review: Defining On-Treatment Remission in Plaque Psoriasis

All News

Cross-Cultural Drivers of Psychosocial Burden in Vitiligo

TRuE-V Data Suggest 2 Years Is the True Benchmark for Ruxolitinib Response

Trending on Dermatology Times

FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults

EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data

Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance

Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS

Don't Be Rash: Balancing Topical Steroids in the Era of Nonsteroidals